Literature DB >> 6435770

European Ethical Review Committee: the experience of an international ethics committee reviewing protocols for drug trials.

J M Faccini, P N Bennett, J L Reid.   

Abstract

An international ethics review committee, founded seven years ago, has several unusual features: it selects its own members, who are independent of the drug industry; it includes members with no medical or paramedical background, such as lay people and lawyers; and it reviews protocols together with the study's sponsor. Membership of 31 from nine European countries enables frequent meetings and there is a full meeting of the committee every year to review progress and consider policy. Of the first 294 protocols for phase I, II, or III trials reviewed, 37 were admitted outright, 243 were amended (usually during the discussion of the protocol), and 14 were rejected. It is suggested that, to overcome the problem of ethics review in smaller institutions, regional health authorities in Britain might consider establishing similar committees.

Entities:  

Keywords:  Biomedical and Behavioral Research; European Ethical Review Committee

Mesh:

Year:  1984        PMID: 6435770      PMCID: PMC1443011          DOI: 10.1136/bmj.289.6451.1052

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  2 in total

1.  Consent in clinical trials: will verbal assent suffice?

Authors:  Tim Beardsley; Martin Flanagan
Journal:  Nature       Date:  1983 Feb 3-9       Impact factor: 49.962

2.  Research ethical committees in Scotland.

Authors:  I E Thompson; K French; K M Melia; K M Boyd; A A Templeton; B Potter
Journal:  Br Med J (Clin Res Ed)       Date:  1981-02-28
  2 in total
  2 in total

Review 1.  The role of attorneys on hospital ethics committees: potential influence on committee decisionmaking.

Authors:  A Helm; D J Mazur
Journal:  HEC Forum       Date:  1989

2.  Treatment of vaginal candidiasis with a single oral dose of fluconazole. Multicentre Study Group.

Authors: 
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.